We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01355393
Recruitment Status : Completed
First Posted : May 18, 2011
Last Update Posted : February 10, 2020
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Washington

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This randomized phase I/II trial studies the side effects and best dose of rintatolimod when given together with vaccine therapy and sargramostim (GM-CSF) to see how well it works in treating patients with stage II-IV human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Vaccines made from synthetic HER2/neu peptides may help the body build an effective immune response to kill tumor cells that express HER-2/neu. Adjuvant therapies, such as GM-CSF and rintatolimod, are additional cancer treatments given after the primary treatment to lower the risk that the cancer will come back and are one way to help vaccines produce stronger immune responses. Giving vaccine therapy together with rintatolimod and/or GM-CSF may be a safe and effective treatment for breast cancer.

Condition or disease Intervention/treatment Phase
HER2-positive Breast Cancer Male Breast Cancer Recurrent Breast Cancer Stage II Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Biological: HER-2/neu peptide vaccine Biological: sargramostim Drug: rintatolimod Phase 1 Phase 2

Detailed Description:

OBJECTIVES:

I. To choose the most promising (maximum biologic dose [MBD]) of five different doses (4, 20, 79, 495 and 2000 mcg) of Ampligen (rintatolimod) administered intradermally (i.d.) as an adjuvant with HER2 vaccination, with respect to toxicity and incidence and magnitude of immune response.

II. To determine, using MBD of Ampligen (defined in first primary aim), whether Ampligen when given with GM-CSF as a combined adjuvant strategy with HER2 vaccination increases both the incidence and magnitude of HER2 Th1 immunity as compared to the standard GM-CSF adjuvant strategy.

OUTLINE: This will be a phase I-II randomized two-stage HER2 vaccine study in breast cancer patients.

STUDY STAGE I: There are five groups of patients randomized to 1 of 5 arms with each arm receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses) given i.d.

STUDY STAGE II: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive the synthetic HER-2/neu peptide vaccine admixed with rintatolimod given i.d.

ARM II: 24 patients will receive the HER-2/neu peptide vaccine admixed with GM-CSF and the other 24 patients will receive the HER-2/neu peptide vaccine admixed with GM-CSF in addition to rintatolimod (dose set by Stage I group that had the most active response) given i.d.

In both study stages, treatment repeats every month for up to 3 months in the absence of disease progression or unacceptable toxicity.

After completion of last vaccine, patients are followed up at 1 and 12 months.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I-II Study of HER2 Vaccination With Poly(I) • Poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients
Study Start Date : July 2011
Actual Primary Completion Date : November 2013

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Stage I, Arm 1 (HER-2/neu peptide vaccine and rintatolimod)

Arm 1: HER2 peptide vaccine + 4 mcg Ampligen®

Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses).

 Biological: HER-2/neu peptide vaccine
Given ID
Other Name: HER-2

Drug: rintatolimod
Given ID
Other Names:
  • Ampligen
  • atvogen
  • poly(I):poly(C12U) RNA
Active Comparator: Stage II, Arm I (HER-2/neu peptide vaccine and sargramostim)
Patients receive synthetic HER-2/neu peptide vaccine admixed with GM-CSF ID.
 Biological: HER-2/neu peptide vaccine
Given ID
Other Name: HER-2

Biological: sargramostim
Given ID
Other Names:
  • GM-CSF
  • Leukine
  • Prokine
Experimental: Stage II, Arm II (HER-2 vaccine, sargramostim, rintatolimod)
Patients receive synthetic HER-2/neu peptide vaccine admixed with GM-CSF and rintatolimod ID
 Biological: HER-2/neu peptide vaccine
Given ID
Other Name: HER-2

Biological: sargramostim
Given ID
Other Names:
  • GM-CSF
  • Leukine
  • Prokine

Drug: rintatolimod
Given ID
Other Names:
  • Ampligen
  • atvogen
  • poly(I):poly(C12U) RNA
Experimental: Stage I, Arm 2 (HER-2/neu peptide vaccine and rintatolimod)

Arm 2: HER2 peptide vaccine + 20 mcg Ampligen®

Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses).

 Biological: HER-2/neu peptide vaccine
Given ID
Other Name: HER-2

Drug: rintatolimod
Given ID
Other Names:
  • Ampligen
  • atvogen
  • poly(I):poly(C12U) RNA
Experimental: Stage I, Arm 3 (HER-2/neu peptide vaccine and rintatolimod)

Arm 3: HER2 peptide vaccine + 79 mcg Ampligen®

Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses).

 Biological: HER-2/neu peptide vaccine
Given ID
Other Name: HER-2

Drug: rintatolimod
Given ID
Other Names:
  • Ampligen
  • atvogen
  • poly(I):poly(C12U) RNA
Experimental: Stage I, Arm 4 (HER-2/neu peptide vaccine and rintatolimod)

Arm 4: HER2 peptide vaccine + 495 mcg Ampligen®

Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses).

 Biological: HER-2/neu peptide vaccine
Given ID
Other Name: HER-2

Drug: rintatolimod
Given ID
Other Names:
  • Ampligen
  • atvogen
  • poly(I):poly(C12U) RNA
Experimental: Stage I; Arm 5 (HER-2/neu peptide vaccine and rintatolimod)

Arm 5: HER2 peptide vaccine + 2000 mcg Ampligen®

Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses).

 Biological: HER-2/neu peptide vaccine
Given ID
Other Name: HER-2

Drug: rintatolimod
Given ID
Other Names:
  • Ampligen
  • atvogen
  • poly(I):poly(C12U) RNA


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Evaluation of immune response among the different treatment arms in Stage I and II [ Time Frame: Up to 12 months post-vaccination ]
    Standard interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) assay will be used to evaluate CD4+ 1 T cell responses to HER2 immunizing peptides.

  2. Evaluation of safety and systemic toxicity among the different treatment arms in Stage I and II [ Time Frame: Up to 4 months ]
    Toxicity grading will be evaluated per Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) 4.0 and monitoring of adverse events (AEs) will be done per Food and Drug Administration (FDA) and National Cancer Institute (NCI) guidelines.


Secondary Outcome Measures :
  1. Disease-free survival [ Time Frame: Time from study enrollment to time of first event, assessed up to 12 months post-vaccination ]
    Though not statistically powered to this endpoint, large differences if observed between the vaccine treatment groups will be noted and described.

  2. Overall survival [ Time Frame: Time from study enrollment to time of first event, assessed up to 12 months post-vaccination ]
    Though not statistically powered to this endpoint, large differences if observed between the vaccine treatment groups will be noted and described.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with stage II, or III HER2+ breast cancer who have completed definitive standard treatment and are in complete remission - or -

  • Patients with stage IV HER2+ breast cancer treated to:

    • No evidence of disease, or
    • Stable bone only disease after definitive therapy

  • Patients must have demonstrated HER2 positive disease, by one of the following methods:

    • Immunohistochemical (IHC) staining of 1+, 2+ or 3+ for the HER2 protein, or
    • Amplification of the HER2 gene on fluorescence in situ hybridization (FISH)
  • Patients must be at least 14 days post cytotoxic chemotherapy prior to enrollment
  • Patients must be at least 14 days post systemic steroids prior to enrollment
  • Patients on bisphosphonates or continued hormone therapy are eligible
  • Men and women of reproductive ability must agree to contraceptive use during the entire study period
  • Patients must have Zubrod Performance Status Score of =< 2
  • Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment
  • White blood cell count (WBC) >= 3000/mm^3
  • Hemoglobin (Hgb) >= 10 mg/dl
  • Serum creatinine =< 2.0 mg/dl or creatinine clearance > 60 ml/min
  • Total bilirubin =< 1.5 mg/dl
  • Serum glutamic oxaloacetic transaminase (SGOT) =< 2.5 times the upper limit of normal
  • Patients on trastuzumab monotherapy must have adequate cardiac function as demonstrated by normal ejection fractions (EF) on multi gated acquisition scan (MUGA) scan or echocardiogram performed within the last 3 months of eligibility sign off

Exclusion Criteria:

  • Restrictive cardiomyopathy
  • Unstable angina within 6 months prior to enrollment
  • New York Heart Association functional class III-IV heart failure
  • Symptomatic pericardial effusion
  • Patients with any contraindication to receiving rhuGM-CSF based products
  • Patients with any clinically significant autoimmune disease requiring active treatment
  • Patients receiving any concurrent immunomodulators within 30 days of eligibility sign-off
  • Patients who are pregnant or breast-feeding
  • Patients who are simultaneously enrolled in any other treatment study
  • Patients who have received a previous HER2 breast cancer vaccine
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01355393


Locations
Layout table for location information
United States, Washington
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States, 98109
Sponsors and Collaborators
University of Washington
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Lupe Salazar Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: University of Washington
ClinicalTrials.gov Identifier: NCT01355393    
Other Study ID Numbers: 7425
NCI-2011-00658 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
7425/133
133 [Tumor Vaccine Group]
7425 ( Other Identifier: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium )
P30CA015704 ( U.S. NIH Grant/Contract )
First Posted: May 18, 2011    Key Record Dates
Last Update Posted: February 10, 2020
Last Verified: June 2019
Keywords provided by University of Washington:
Breast Cancer
HER2+
Vaccine
 Stage II
Stage III
Stage IV
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Breast Neoplasms, Male
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
 poly(I).poly(c12,U)
Sargramostim
Immunologic Factors
Physiological Effects of Drugs
Antiviral Agents
Anti-Infective Agents